Ventas Inc. logo

Ventas Inc. (VTR)

Market Closed
2 Mar, 20:00
NYSE NYSE
$
86. 66
+0.5
+0.58%
Pre Market
$
87. 00
+0.34 +0.39%
41.16B Market Cap
2,467.5 P/E Ratio
3.61% Div Yield
1,566,230 Volume
0 Eps
$ 86.16
Previous Close
Day Range
85.95 86.94
Year Range
60.15 87.87
Want to track VTR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
VTR earnings report is expected in 56 days (28 Apr 2026)
Why Ventas (VTR) is a Top Dividend Stock for Your Portfolio

Why Ventas (VTR) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Ventas (VTR) have what it takes?

Zacks | 6 months ago
Ventas Stock Gains 15.5% Year to Date: Will It Continue to Rise?

Ventas Stock Gains 15.5% Year to Date: Will It Continue to Rise?

VTR stock rallies 15.5% YTD as strong SHOP growth, accretive investments and a solid balance sheet fuel momentum.

Zacks | 6 months ago
Ventas Selects Discovery Senior Living to Operate its 15 Communities

Ventas Selects Discovery Senior Living to Operate its 15 Communities

VTR taps Discovery Senior Living to run 15 communities, expanding a partnership aimed at boosting performance and value creation.

Zacks | 6 months ago
Ventas (VTR) Could Be a Great Choice

Ventas (VTR) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Ventas (VTR) have what it takes?

Zacks | 6 months ago
Ventas Q2 FFO and Revenues Top Estimates, Same-Store Cash NOI Rises

Ventas Q2 FFO and Revenues Top Estimates, Same-Store Cash NOI Rises

VTR's Q2 results reflect a year-over-year rise in revenues. The total property same-store NOI improves on strong performance across the business segments.

Zacks | 7 months ago
Ventas, Inc. (VTR) Q2 2025 Earnings Call Transcript

Ventas, Inc. (VTR) Q2 2025 Earnings Call Transcript

Ventas, Inc. (NYSE:VTR ) Q2 2025 Earnings Conference Call July 31, 2025 10:00 AM ET Company Participants Bill Grant - Senior Vice President of Investor Relations Debra A. Cafaro - Chairman & CEO J.

Seekingalpha | 7 months ago
Ventas (VTR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Ventas (VTR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Ventas (VTR) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks | 7 months ago
Ventas (VTR) Beats Q2 FFO and Revenue Estimates

Ventas (VTR) Beats Q2 FFO and Revenue Estimates

Ventas (VTR) came out with quarterly funds from operations (FFO) of $0.87 per share, beating the Zacks Consensus Estimate of $0.85 per share. This compares to FFO of $0.8 per share a year ago.

Zacks | 7 months ago
Ahead of Ventas (VTR) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Ahead of Ventas (VTR) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Beyond analysts' top-and-bottom-line estimates for Ventas (VTR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.

Zacks | 7 months ago
What's in the Offing for Ventas Stock This Earnings Season?

What's in the Offing for Ventas Stock This Earnings Season?

While VTR's Q2 earnings are likely to have benefited from favorable SHOP operating trends and a well-diversified tenant base, high interest expenses may have hurt it.

Zacks | 7 months ago
Ventas (VTR) Could Be a Great Choice

Ventas (VTR) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Ventas (VTR) have what it takes?

Zacks | 7 months ago
Ventas Stock Gains 11.6% in 6 Months: Will the Trend Last?

Ventas Stock Gains 11.6% in 6 Months: Will the Trend Last?

VTR is likely to gain from an aging population, rising healthcare expenses, favorable outpatient visit trends and accretive investments in its research portfolio.

Zacks | 7 months ago
Loading...
Load More